Puma Biotechnology Prices Public Offering of Common Stock
October 19 2016 - 11:18PM
Business Wire
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical
company, announced the pricing of an underwritten public offering
of 3,750,000 shares of its common stock at a public offering price
of $40.00 per share. The offering is expected to close on or about
October 25, 2016, subject to customary closing conditions. The
Company has granted the underwriters a 30-day option to purchase up
to 562,500 additional shares of its common stock at the public
offering price, less underwriting discounts and commissions. All of
the shares are being sold by Puma Biotechnology.
Citigroup and J.P. Morgan are acting as lead book-running
managers, Credit Suisse is acting as joint book-running manager and
BofA Merrill Lynch is acting as lead manager for the offering.
Stifel is acting as co-manager for the offering.
The offering is being made pursuant to an automatically
effective shelf registration statement filed with the Securities
and Exchange Commission (SEC) on January 20, 2015. A preliminary
prospectus supplement describing the terms of the offering has been
filed with the SEC and is available on the SEC’s website at
www.sec.gov. Copies of the preliminary prospectus supplement and
the accompanying prospectus, and when available, the final
prospectus supplement and the accompanying prospectus relating to
the offering may also be obtained by contacting Citigroup Global
Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by phone at (800) 831-9146; J.P.
Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, or by phone at
(866) 803-9204; or Credit Suisse, Attention: Prospectus Department,
One Madison Avenue, New York, NY 10010, by telephone at (800)
221-1037, or by email at newyork.prospectus@credit-suisse.com.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
other jurisdiction.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161019006623/en/
Puma Biotechnology, Inc.Alan H. Auerbach or Mariann Ohanesian,
+1 424 248
6500info@pumabiotechnology.comir@pumabiotechnology.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Apr 2023 to Apr 2024